STOCKHOLM, May 31, 2024 /PRNewswire/ — January 1 -March 31, 2024 The first quarter in figures Net sales were TSEK 6,057 (5,149), +18%. The loss after tax was TSEK 10,861 (10,906). The loss per share was SEK 0.09 (0.15). The cash flow from current operations was negative in the amount of…

STOCKHOLM, May 31, 2024 /PRNewswire/ — Today, 31 May 2024, trading in the new shares and warrants of series TO 2 begins, which were issued by SciBase Holding AB (publ) (“SciBase” or the “Company”) in connection with the capital raising announced by the Company on 5 April 2024, consisting…

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2 In both trials, the primary endpoint of clinical remission (per…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.